Conditions: Chronic Phase Chronic Myeloid Leukemia
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 39
Healthy volunteers: no

Brief summary:
This study proposes to evaluate the number of chronic, Grade 1 or 2, non-hematologic Adverse Events (AEs) that reduce in grade or resolve at 3 months after switching therapy from imatinib to dasatinib.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Dasatinib
Intervention descriptions: intervention 1: tablets, oral, 100 mg, Once daily, Up to12 months on study,

Protocol document: